Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stem cell technology promises better grafts:

This article was originally published in Clinica

Executive Summary

The US company Progenitor has received a patent for its technology for processing blood stem cells capable of developing into blood or blood vessel cells. These could be used in bone marrow transplantation, vascular grafts, coatings and other therapeutic applications. The Menlo Park, California-based firm grows stem cells from the yolk sac, a tissue that appears very briefly in the early development of mammals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel